U.S. Senator Maggie Hassan said on Friday she is launching an investigation into British pharmaceutical giant GlaxoSmithKline's (GSK.L), opens new tab decision to discontinue a widely used asthma inhaler for children. Hassan said in letters sent on Friday to GSK and its authorized generic distributor, Prasco Laboratories, and seen by Reuters that the decision to remove Flovent HFA from the market in January 2024 had contributed to a spike in hospitalizations and deaths linked to asthma complications.
Read more
